Asthma in older adults with severe coronavirus disease 2019

Avdeev, S. N.; Pozdnakova, Anna A.; Gaynitdinova, V. V.; Чикина, С. Ю.; Власенко, А. Е.

doi:10.1016/j.anai.2021.10.016

Cited by 8 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Изучение данных показал, что COVID19 сопровож дался тяжелым течением сопутствующего заболе вания примерно у 23% пациентов и для 6% из них закончился летально. Лица с тяжелыми сопутству ющими заболеваниями были значительно старше (средний возраст -60,4 года; 95% ДИ: 57,8-63,1), чем пациенты, не имеющие тяжелых заболеваний (44,6 года; 95% ДИ: 42,8-46,3, Р < 0,0001).…”

Section: Reviewunclassified

“…В период начала пандемии COVID19 россий ские ученые проводили исследование, в котором изучалось течение COVID19 у пожилых пациентов старше 65 лет, длительно страдавших бронхиаль ной астмой. В ходе исследования выяснилось, что неаллергический фенотип астмы, тяжесть астмы, системное применение стероидов и сопутствующие заболевания могут быть факторами риска неблаго приятных исходов у пожилых пациентов с астмой и тяжелой формой COVID19 [44].…”

Section: Sarscov2 и бронхиальная астмаunclassified

See 1 more Smart Citation

Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19

Svist,

Torchinsky,

Briko

et al. 2024

Epidemiology and Vaccinal Prevention

Self Cite

View full text Add to dashboard Cite

Relevance. As is known, the presence of some concomitant diseases may be directly related to the severe course of Coronavirus infection and high mortality among the sick. However, the question of the possible impact of bronchial asthma and COPD on outcomes and survival rates in patients with COVID-19 remains relevant. Aim. To evaluate, according to the literature, the prevalence of bronchial asthma and COPD in the general population and among COVID-19 patients in the Russian Federation and in the world, and to determine the degree of their influence on outcomes. Materials and methods. The results of 1080 previously conducted domestic and foreign studies were studied, from which 46 papers were selected that meet the inclusion criteria. Based on the data presented in the studies on the prevalence of bronchial asthma and COPD, the analysis of survival rates, mortality and severity of the consequences of COVID-19 in patients with these pathologies was carried out. Results and discussions. Patients with COPD often had a more severe course of COVID-19, as well as high mortality rates due to the rapid progression of the pulmonary process. Earlier it was reported that patients with bronchial asthma did not notice a negative effect of COVID-19, but the results of recent studies prove the opposite, and therefore further observations are required in this cohort of patients. Conclusion.

show abstract

Section: Reviewunclassified

Section: Sarscov2 и бронхиальная астмаunclassified

Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19

Svist,

Torchinsky,

Briko

et al. 2024

Epidemiology and Vaccinal Prevention

Self Cite

View full text Add to dashboard Cite

show abstract

“…во время госпитализации по сравнению с группой выживших: 60% [36-80] (n = 9) против 5% [2][3][4][5][6][7][8][9][10][11] (n = 4), p < 0,001. Также был проведен анализ распространенности сопутствующих заболеваний в группах исследования (рис.…”

Section: Covid-19unclassified

“…В исследованиях представлены многочисленные факторы, которые могут играть роль в восприимчивости и тяжести COVID-19 у пациентов с БА [8]. Они включают в себя тяжесть самой астмы, ее фенотип (аллергический или неаллергический), лечение (принимаются системные кортикостероиды или нет), сопутствующие заболевания и возраст [9][10][11][12][13].…”

Section: Introductionunclassified

Analysis of severity and evaluation of prognosis in elderly patients with bronchial asthma and severe COVID-19

et al. 2023

Self Cite

View full text Add to dashboard Cite

Introduction. The role of comorbid conditions in susceptibility to SARS-CoV-2 infection and the severity of associated COVID-19 disease has been an area of ongoing research since the pandemic began.Objective. To evaluate the impact of elderly asthma on the clinical course and outcomes of severe COVID-19.Materials and methods. Elderly patients (WHO, 2020) (> 60 years, n = 131) with bronchial asthma (BA) hospitalized for severe COVID-19 were included in the study. The presence of COVID-19 was confirmed by laboratory tests (PCR smear) and/or clinical and radiological examinations. All patients had a history of a confirmed diagnosis of bronchial asthma (GINA, 2020). Follow-up was performed at the hospital stage and for 90 days after discharge from the hospital.Results. In the groups of patients with lethal outcome (regardless of the stage) there were statistically significantly higher Charlson index, respiratory rate, CT lung lesion volume, leukocyte, neutrophil and neutrophil to lymphocyte ratios, lower absolute eosinophil count. In the group of patients who died during hospitalization, severe (IV–V) asthma (p = 0.03), steroid use during the previous year (p = 0.02), chronic heart failure (p = 0.009), and the atopic asthma phenotype was less common (p = 0.02). Those who died in the 90-day posthospital period had greater lung lesion volume on CT scan, and diabetes mellitus was more common (p < 0.001). The most significant predictors of mortality were identified.Conclusion. The common most significant predictors of hospital and 90-day posthospital mortality in older patients with bronchial asthma were comorbidity index and lower eosinophil levels. Hospital mortality is further characterized by a higher neutrophil to lymphocyte ratio and lower total protein; 90-day posthospital mortality by the amount of lung damage on CT scan and the presence of diabetes mellitus.

show abstract

“…In this process, it has been suggested that the asthma phenotype produces different responses to a SARS-CoV-2 infection. There are studies which find a better prognosis or lower risk of disease for patients with the T2 versus the non-T2 phenotype, in patients with early-onset versus late-onset asthma, and in allergic versus non-allergic patients [ 15 – 17 ].…”

mentioning

confidence: 99%

The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids

et al. 2022

View full text Add to dashboard Cite

In December 2019, a pneumonia outbreak of unknown origin was identified in Wuhan, China. It was given the label coronavirus disease 2019 (COVID-19) and the virus causing it was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2]. On 11 March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a pandemic [3]. By 5 April 2022, there had been 490 853 129 confirmed cases of COVID-19, including 6 155 344 deaths, reported to the WHO [4]. As of 4 April 2022, a total of 11 183 087 530 vaccine doses had been administered but, despite this, there is still a relevant case incidence rate throughout the world [4]. In the last few months of the pandemic, factors associated with a higher incidence rate or worse prognosis of COVID-19 have been identified, such as older age, obesity, high blood pressure and diabetes mellitus [5–8].

show abstract

Asthma in older adults with severe coronavirus disease 2019

Cited by 8 publications

References 11 publications

Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19

Prevalence of Bronchial Asthma and COPD in Comorbidity with COVID-19

Analysis of severity and evaluation of prognosis in elderly patients with bronchial asthma and severe COVID-19

The polyhedric reality of the interaction between COVID-19, asthma and inhaled corticosteroids

Contact Info

Product

Resources

About